Reuters logo
BRIEF-Novo Nordisk's Xultophy offers greater weight reductions than Iglarlixi
December 4, 2017 / 7:13 AM / 15 days ago

BRIEF-Novo Nordisk's Xultophy offers greater weight reductions than Iglarlixi

Dec 4 (Reuters) - NOVO NORDISK SAYS:

* XULTOPHY CAN DELIVER GREATER REDUCTIONS IN THE OVERALL BLOOD SUGAR LEVELS AND WEIGHT FOR PEOPLE WITH TYPE 2 DIABETES WHO ARE UNCONTROLLED ON BASAL INSULIN, COMPARED TO IGLARLIXI

* NEW FINDINGS ARE FROM AN INDIRECT COMPARISON BETWEEN XULTOPHY AND IGLARLIXI PUBLISHED IN THE JOURNAL OF MEDICAL ECONOMICS

* THE ANALYSIS IS BASED ON PUBLISHED DATA FROM INDIVIDUAL CLINICAL TRIALS WHICH INVOLVED OVER 700 ADULTS LIVING WITH TYPE 2 DIABETES

* PEOPLE WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN ACHIEVED A 0.44 PCT GREATER REDUCTION OF THEIR OVERALL BLOOD SUGAR LEVELS (HBA(1C)), AND A 1.42 KG GREATER WEIGHT LOSS WHEN TREATED WITH XULTOPHY, COMPARED TO THOSE TREATED WITH IGLARLIXI, AT SIMILAR DOSES OF INSULIN. FURTHER COMPANY COVERAGE:

Copenhagen newsroom

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below